S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Small Pharma (DMT) Stock Price, News & Analysis

C$0.15
-0.01 (-6.25%)
(As of 10/20/2023)
Compare
Today's Range
C$0.15
C$0.16
50-Day Range
C$0.15
C$0.19
52-Week Range
C$0.06
C$0.22
Volume
1.89 million shs
Average Volume
296,159 shs
Market Capitalization
C$50.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

DMT stock logo

About Small Pharma Stock (CVE:DMT)

Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc.

DMT Stock Price History

DMT Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Closing Bell: Small Pharma Inc down on Monday (DMT)
Closing Bell: Small Pharma Inc up on Monday (DMT)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Closing Bell: Small Pharma Inc down on Wednesday (DMT)
Closing Bell: Small Pharma Inc up on Friday (DMT)
Closing Bell: Small Pharma Inc down on Thursday (DMT)
Small Pharma Announces SPL028 R&D Strategy Update
Closing Bell: Small Pharma Inc flat on Friday (DMT)
Closing Bell: Small Pharma Inc flat on Monday (DMT)
Closing Bell: Small Pharma Inc down on Friday (DMT)
Closing Bell: Small Pharma Inc up on Wednesday (DMT)
Closing Bell: Small Pharma Inc flat on Wednesday (DMT)
See More Headlines
Receive DMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Small Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/19/2023
Today
12/10/2023
Next Earnings (Estimated)
1/24/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
C$-19,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$-1,162.00
Price / Sales
-43,343.80
Cash Flow
C$0.13 per share
Book Value
C$0.03 per share

Miscellaneous

Free Float
N/A
Market Cap
C$50.37 million
Optionable
Not Optionable
Beta
0.86
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. George Tziras
    CEO & Non-Independent Director
  • Mr. David Steel
    Chief Financial Officer
  • Dr. Carol Routledge
    Chief Scientific & Medical Officer
  • Ms. Marie Claire Layzell (Age 46)
    Chief Manufacturing & Development Officer & Director
    Comp: $457.93k
  • Dr. Alastair James Riddell M.D. (Age 74)
    M.Sc., MBChB, MFPM, MRCGP, Ph.D., Chief Operating Officer
  • Ms. Jenny Maguire
    Head of Brand & Communications
  • Ms. Emma Hodge
    Head of Intellectual Property
  • Mr. Richard M. Kimel HBA (Age 56)
    LLB, Corporate Secretary
  • Ms. Sarah Hamilton
    Group Financial Controller
  • Mr. Jim Rennie
    Director of Development and Member of Scientific & Advisory Board














DMT Stock Analysis - Frequently Asked Questions

Should I buy or sell Small Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Small Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DMT shares.
View DMT analyst ratings
or view top-rated stocks.

How have DMT shares performed in 2023?

Small Pharma's stock was trading at C$0.09 on January 1st, 2023. Since then, DMT shares have increased by 66.7% and is now trading at C$0.15.
View the best growth stocks for 2023 here
.

When is Small Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 24th 2024.
View our DMT earnings forecast
.

How were Small Pharma's earnings last quarter?

Small Pharma Inc. (CVE:DMT) issued its quarterly earnings data on Thursday, October, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of Small Pharma?

Shares of DMT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:DMT) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -